Delving into the Latest Updates on Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]

Active Indication

Brenner Tumor

Inactive Indication

Endometrioid carcinoma ovaryFallopian Tube Clear Cell AdenocarcinomaMucinous Adenocarcinoma+ [16]

Originator Organization

Mayo Clinic

Active Organization

Mayo Clinic

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

Start Date13 Mar 2015

Sponsor / Collaborator

Mayo Clinic

NCT02068794

/ Active, not recruitingPhase 1/2IIT

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.

Start Date25 Apr 2014

Sponsor / Collaborator

Mayo Clinic

[+1]

100 Clinical Results associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Translational Medicine associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Patents (Medical) associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Deals associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrioid carcinoma ovary	Phase 2	United States	Mayo Clinic	13 Mar 2015
Fallopian Tube Clear Cell Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Mucinous Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian Carcinosarcoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian clear cell adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian mixed epithelial carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian Mucinous Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian Serous Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Platinum-Resistant Fallopian Tube Carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02364713 (MC1365, CTgov)	Phase 2	Primary Peritoneal Transitional Cell Carcinoma \| Recurrent Primary Peritoneal Carcinoma \| Undifferentiated Ovarian Carcinoma ... View more	17	Quality-of-Life Assessment+Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (Arm A (MV-NIS))	fnjonelxuy(uiptlcjtti) = awmfvbvpom kzlxhpqafy (gamntuttmx, lgaopwoyag - aouqtzfbgk) View more	-	17 Nov 2025
				Quality-of-Life Assessment+Pegylated Liposomal Doxorubicin Hydrochloride+Gemcitabine Hydrochloride+Paclitaxel+Bevacizumab+Topotecan Hydrochloride (Arm B (DOXIL, GEM, TOPA, TAXOL))	fnjonelxuy(uiptlcjtti) = deuwtjaggt kzlxhpqafy (gamntuttmx, nhaoblfidd - vbbpxukyqy) View more
NCT02068794 (CTgov)	Phase 1/2	Recurrent Primary Peritoneal Carcinoma \| Undifferentiated Ovarian Carcinoma \| Ovarian clear cell adenocarcinoma ... View more	34	MV-NIS infected MSC (Phase I Dose Level 0)	glljzidato = btaenfolft pwogiobynm (tcqxwvoxgo, uaorawskuz - nbtvthbktt) View more	-	16 Jul 2025
				MV-NIS (Phase I Dose Level 1)	glljzidato = mriryorgyb pwogiobynm (tcqxwvoxgo, tpsalrazyo - synjawctpi) View more